RS63940B1 - Azelastin za antivirusno lečenje - Google Patents

Azelastin za antivirusno lečenje

Info

Publication number
RS63940B1
RS63940B1 RS20230083A RSP20230083A RS63940B1 RS 63940 B1 RS63940 B1 RS 63940B1 RS 20230083 A RS20230083 A RS 20230083A RS P20230083 A RSP20230083 A RS P20230083A RS 63940 B1 RS63940 B1 RS 63940B1
Authority
RS
Serbia
Prior art keywords
azelastin
antivirus treatment
antivirus
treatment
Prior art date
Application number
RS20230083A
Other languages
English (en)
Serbian (sr)
Inventor
Eszter Nagy
Gábor Nagy
Valeria Szijarto
Robert Konrat
Original Assignee
CEBINA GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20184767.0A external-priority patent/EP3936132A1/en
Application filed by CEBINA GmbH filed Critical CEBINA GmbH
Publication of RS63940B1 publication Critical patent/RS63940B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RS20230083A 2020-05-29 2021-05-28 Azelastin za antivirusno lečenje RS63940B1 (sr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP20177451 2020-05-29
EP20184767.0A EP3936132A1 (en) 2020-07-08 2020-07-08 Azelastine as antiviral treatment
EP20195740 2020-09-11
EP21171333 2021-04-29
EP21727186.5A EP3934653B1 (en) 2020-05-29 2021-05-28 Azelastine as antiviral treatment
PCT/EP2021/064338 WO2021239943A1 (en) 2020-05-29 2021-05-28 Azelastine as antiviral treatment

Publications (1)

Publication Number Publication Date
RS63940B1 true RS63940B1 (sr) 2023-02-28

Family

ID=76059910

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20230083A RS63940B1 (sr) 2020-05-29 2021-05-28 Azelastin za antivirusno lečenje

Country Status (21)

Country Link
US (3) US20230201216A1 (https=)
EP (2) EP3934653B1 (https=)
JP (1) JP2023529025A (https=)
KR (1) KR20230021009A (https=)
CN (1) CN116406273A (https=)
AU (1) AU2021279280A1 (https=)
BR (1) BR112022023897A2 (https=)
CA (1) CA3184167A1 (https=)
DK (1) DK3934653T3 (https=)
ES (1) ES2937145T3 (https=)
FI (1) FI3934653T3 (https=)
HU (1) HUE060929T2 (https=)
IL (1) IL298543A (https=)
JO (1) JOP20220319B1 (https=)
LT (1) LT3934653T (https=)
MX (1) MX2022015074A (https=)
PL (1) PL3934653T3 (https=)
RS (1) RS63940B1 (https=)
SI (1) SI3934653T1 (https=)
SM (1) SMT202300036T1 (https=)
WO (1) WO2021239943A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11806359B2 (en) 2020-03-31 2023-11-07 Phoenix Biotechnology, Inc. Method and compositions for treating Coronavirus infection
ES2937145T3 (es) * 2020-05-29 2023-03-24 CEBINA GmbH Azelastina como tratamiento antiviral

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3877904D1 (de) * 1987-11-13 1993-03-11 Asta Pharma Ag Azelastin enthaltende arzneimittel zur anwendung in der nase und/oder am auge.
DE3836579A1 (de) * 1987-11-13 1989-05-24 Asta Pharma Ag Azelastin enthaltende arzneimittel zur anwendung in der nase und/oder am auge
US20100311656A1 (en) * 2003-04-23 2010-12-09 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides
US8758816B2 (en) * 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
JP2008285474A (ja) 2007-04-17 2008-11-27 Daiichi Sankyo Healthcare Co Ltd 抗アデノウイルス剤を含有する医薬組成物
US8642069B2 (en) * 2008-08-27 2014-02-04 Alexander D. Goldin Composition and method for treating colds
WO2021207213A2 (en) * 2020-04-07 2021-10-14 University Of Florida Research Foundation, Incorporated Methods to prevent sars-cov-2 infection and treat covid-19
US20230142221A1 (en) * 2020-04-10 2023-05-11 Kamal Khan Mubarak Compositions and methods for modulating ace2 receptor
CN113521289A (zh) * 2020-04-16 2021-10-22 中国科学院上海药物研究所 15种药物有效成分在抗病毒感染中的应用
ES2937145T3 (es) * 2020-05-29 2023-03-24 CEBINA GmbH Azelastina como tratamiento antiviral

Also Published As

Publication number Publication date
AU2021279280A1 (en) 2023-01-05
EP3934653A1 (en) 2022-01-12
SMT202300036T1 (it) 2023-03-17
MX2022015074A (es) 2023-02-16
PL3934653T3 (pl) 2023-03-13
US11273163B2 (en) 2022-03-15
EP4190333A1 (en) 2023-06-07
HUE060929T2 (hu) 2023-04-28
EP3934653B1 (en) 2022-11-09
FI3934653T3 (fi) 2023-03-01
IL298543A (en) 2023-01-01
BR112022023897A2 (pt) 2023-04-04
KR20230021009A (ko) 2023-02-13
ES2937145T3 (es) 2023-03-24
WO2021239943A1 (en) 2021-12-02
SI3934653T1 (sl) 2023-04-28
CN116406273A (zh) 2023-07-07
CA3184167A1 (en) 2021-12-02
JOP20220319B1 (ar) 2024-12-22
JP2023529025A (ja) 2023-07-06
US11433080B2 (en) 2022-09-06
US20230201216A1 (en) 2023-06-29
US20210369730A1 (en) 2021-12-02
LT3934653T (lt) 2023-02-27
DK3934653T3 (da) 2023-02-13
US20220143040A1 (en) 2022-05-12

Similar Documents

Publication Publication Date Title
IL285496A (en) Methods for treating cholestasis
SI3986897T1 (sl) Inhibitor EGFR za zdravljenje raka
IL285771A (en) Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
IL261015B (en) Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer
EP3706737A4 (en) ASH11 INHIBITORS AND METHOD OF TREATING THEREOF
EA201692091A1 (ru) Хиноксалиновые соединения и их применение
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
EP3340971A4 (en) METHOD FOR TREATING LENNOX-GASTAUT SYNDROME WITH FENFLURAMINE
EP3773633A4 (en) METHODS OF TREATMENT OF GLIOBLASTOMA
IL279993A (en) C-mannoside compounds useful for the treatment of urinary tract infections
IL261047A (en) Taf1 inhibitors for the therapy of cancer
EP4493175A4 (en) MIRDAMETINIB TREATMENT
EP4188608A4 (en) TREATMENT METHOD
LT4034122T (lt) Hiperfenilalaninemijos gydymo būdai
EP3787625A4 (en) METHODS OF TREATMENT OF CANCER
EP3852816A4 (en) METHODS OF TREATMENT OF CANCER
EP3386507A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF STOMACH DISEASES
EP4008696A4 (en) SURFACE TREATMENT AGENT
EP4001364A4 (en) Surface treatment agent
IL281775A (en) Methods of treatment of infections using bacteria
RS63940B1 (sr) Azelastin za antivirusno lečenje
EP3713576A4 (en) METHOD OF CANCER THERAPY
EP3532063A4 (en) POLYTHERAPY FOR THE TREATMENT OF PULMONARY HYPERTENSION
EP4272094A4 (en) EDIT SETTINGS
EP4117655A4 (en) Treatment methods